{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000099","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.156341+00:00","generated_at":"2026-05-29T05:12:21.522699+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Keros reports elritercept Phase 2 data: 134.1 wk median TI in MDS; spleen reductions in MF","bullets":["55.2% (48/87) of mITT patients achieved overall erythroid response; median TI duration 134.1 weeks in lower-risk MDS.","31.4% (16/51) of high-transfusion-burden MDS patients achieved TI >=8 weeks; 50% of those had TI >=24 weeks.","In MF, 63.4% (26/41) of transfusion-dependent patients had reduced RBC burden; 24.4% achieved TI.","40% (8/20) of MF patients with baseline spleen >=450 cm³ had spleen volume reduction at week 24; 3 had >=35% reduction.","Elritercept generally well-tolerated; Phase 3 RENEW trial in MDS expected to begin enrollment soon."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000099","json":"https://secwatch.observer/filing/0001664710-24-000099.json","markdown":"https://secwatch.observer/filing/0001664710-24-000099.md","text":"https://secwatch.observer/filing/0001664710-24-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000099/0001664710-24-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000099/kros-20241209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:12:21.522699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}